|
Synonyms: MORAb-022
Compound class:
Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 [1], and these sequences belong to monoclonal antibody clone G9 specified in the patent.
|
| References |
|
1. Sass PM, Nicolaides NE, Grasso L, Li J, Chao Q, Routhier E, Ebel W. (2007)
Antigenic gm-csf peptides and antibodies to gm-csf. Patent number: WO2007092939. Assignee: Morphotek, Inc.. Priority date: 08/02/2006. Publication date: 16/08/2007. |
